Compare RICK & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RICK | LYEL |
|---|---|---|
| Founded | 1983 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 196.2M | 195.8M |
| IPO Year | 1996 | 2021 |
| Metric | RICK | LYEL |
|---|---|---|
| Price | $28.77 | $16.92 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $38.38 |
| AVG Volume (30 Days) | 30.2K | ★ 220.6K |
| Earning Date | 08-06-2026 | 11-04-2026 |
| Dividend Yield | ★ 1.11% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $144,896,000.00 | $36,000.00 |
| Revenue This Year | $16.98 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $181.22 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $20.76 | $7.20 |
| 52 Week High | $32.00 | $45.00 |
| Indicator | RICK | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 58.34 | 79.50 |
| Support Level | $25.21 | $15.49 |
| Resistance Level | $29.32 | $16.97 |
| Average True Range (ATR) | 1.04 | 1.28 |
| MACD | 0.23 | 0.82 |
| Stochastic Oscillator | 61.25 | 98.80 |
RCI Hospitality Holdings Inc through its subsidiaries, owns and operates establishments that offer live adult entertainment, restaurant, and or bar operations. It also owns and operates a communication company serving the adult nightclub industry. The company's operating business segments are Nightclubs, Bombshells, and Others. It operates nightclubs through the following brands Rick's Cabaret, Vivid Cabaret, Tootsie's Cabaret, Club Onyx, and Jaguars Club. In the Bombshells segment, the company is building a chain of Restaurants and Sports Bars in Dallas, Austin, and Houston, Texas. It derives the majority of revenue from the Nightclubs segment that engages in the sale of alcoholic beverages, food, and merchandise items; service in the form of cover charges, and room rentals.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.